Meet Cromos Pharma’s CEO, Dr. Vlad Bogin in San Antonio, Texas at San Antonio Breast Cancer Symposium (SABCS 2016) on December 6-10, 2016

Cromos Pharma’s CEO, Dr. Vlad Bogin will be speaking at the Boston Biotech CEO Conference that takes place in Boston, USA on 26-27 May 2015

On 27 May 2015 Cromos Pharma’s CEO will be speaking at the Boston Biotech CEO Conference where he will share the podium with the executives from Kairos Pharma, CANbridge Life Sciences and Forma Therapeutics in discussing  the topic of “Game Changers: New Business Models for Maximizing Value‎”.

CONTACT

INQUIRY@CROMOSPHARMA.COM

To arrange an introductory meeting and find out how our experience can benefit your next clinical project.

OUR PUBLICATIONS

Clinical Intelligence Report 6th edition November
Shining a Spotlight on Diabetes Awareness Month: The Vital Role of Clinical Trials
Navigating the Challenging Biotech Funding Landscape | Cromos Pharma
Navigating the Challenging Biotech Funding Landscape
Clinical Research Focus | 22nd Edition. November | Cromos Pharma
Clinical Research Focus. 22nd Edition
Cromos Pharma's CEO Reflections on ESMO 2023
Cromos Pharma’s CEO Reflections on ESMO 2023: A Glimpse into The Future Of Oncology
Fit-for-Purpose Biotech – CRO Collaboration – The FSP Model | Cromos Pharma
Fit-for-Purpose Biotech – CRO Collaboration: The FSP Model
Project Optimus - Enhancing Oncology Drug Dosage Optimization | Cromos Pharma
Enhancing Oncology Drug Dosage Optimization: Project Optimus
Clinical Research Focus | 21st Edition. October | Cromos Pharma
Clinical Research Focus. 21st Edition
Debating the Role of Interchangeability in Biosimilar Development
Debating the Role of Interchangeability in Biosimilar Development
Clinical Research Focus 20th Edition September | Cromos Pharma
Clinical Research Focus. 20th Edition
EMA Releases a Reflection Paper on the Role of AI in Drug Development
EMA Releases a Reflection Paper on the Role of AI in Drug Development
Regulatory Landscapes of GMO Research Programs | Cromos Pharma
Cromos Pharma Contemplates Complex International GMO Research Program Regulations
Decentralized Clinical Trials | Cromos Pharma
Decentralized Clinical Trials: Balancing the Promise and Pitfalls in Cost, Recruitment, and Patient Satisfaction
Clinical research focus 19th edition
Clinical Research Focus. 19th Edition
diversity in clinical trials
Advancing Clinical Trial Diversity: A Step Towards Equitable Healthcare
Clinical Trials in the Czech Republic: A Prominent Hub for Scientific Discovery and Cost Optimization
old people in cancer clinical trials
Addressing the Underrepresentation of Older Adults in Cancer CT: Advancing Inclusion for Improved Care
Real-World Evidence in Clinical Trials
Regulatory Focus Shifts: Expanding Role of Real-World Evidence for Evaluating New and Expanded Drug Indications
Clinical Research Focus 18th Edition Publication
Clinical Research Focus. 18th Edition
Poland clinical research, clinical trials in Poland
Poland: A Thriving Hub for Biotech Advancements and Clinical Trials
ASCO Key Takeaways, ASCO Annual Meeting, ASCO 2023
Insights from ASCO 2023
Clinical Research Focus. 17th Edition
clinical trials in Baltic countries
Clinical Trials in the Baltic States – Countries’ Profile for 2023
FDA's RTOR Program, FDA Real-Time Oncology Review
The Pros and Cons of the FDA’s Real-Time Oncology Review Program
Cromos Pharma's Newsletter: Clinical Research Focus
Clinical Research Focus. 16th Edition
Clinical Trials in Hungary
Clinical Trials in Hungary – Country Profile for 2023
News Digest 15. Clinical Research Focus
Clinical Research Focus. 15th Edition
clinical research in bulgaria, Bulgaria clinical trials
Clinical Trials in Bulgaria – Country Profile for 2023
News Digest Edition 14
Clinical Research Focus. 14th Edition
Clinical Trials in Romania, full article on clinical trials in Romania, clinical research, romanian clinical research
Clinical Trials in Romania – So Much to be Discovered
animal testing, use of animals in clinical trials, animal testing in clinical research
Phasing out of Animal Testing for Next Generation Drugs